Hepion Reports Results of CRV431 in P-IIa AMBITION Trial for the Treatment of NASH

July 14, 2021 Auto Bot Clinical Trials 0

Shots:

  • The P-IIa AMBITION study assessing CRV431 (75/ 225mg, qd, PO given as soft gelatin capsules) vs PBO to presumed F2 and F3 NASH patients for 28days, followed by a 14-day observation period for safety
  • The study met its 1EPs i.e. safety, tolerability & PK with no SAEs at both doses while some patients experienced mild AEs, reductions in liver transaminases indicate dose-related improvements in NASH biomarker, decrease ALT AUCs with increase dose indicating a positive dose-response
  • The company plans to initiate the P-IIb ASCEND-NASH trial in 2021 to evaluate CRV431 in biopsy-proven NASH patients with advanced fibrosis

Click here to read full press release/ article | Ref: Globe Newswire | Image: Hepion Pharma

The post Hepion Reports Results of CRV431 in P-IIa AMBITION Trial for the Treatment of NASH first appeared on PharmaShots.